Every Form 4 that INHIBITOR THERAPTICS INC (INTI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INTI filings page.
Black Robe Capital LLC, a 10% owner of Inhibitor Therapeutics, Inc., together with Chief Financial Officer James A. McNulty as reporting persons, recorded a bona fide gift of 3,200,000 shares of common stock on July 1, 2026. Following this disposition, the reporting holder directly owned 19,901,057 common shares.
OSMAN RONALD E reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. reported that director and ten percent owner Ronald E. Osman received a grant of 50,000 shares of restricted common stock on May 4, 2026 as compensation under the 2014 Equity Incentive Plan, subject to shareholder approval. After this award, reported indirect ownership totals 23,614,985 common shares, consisting of 100,000 shares held by Mr. Osman and the remaining shares held by the Ronald E. Osman Trust III, for which he serves as sole trustee.
Yanez Michelle reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Michelle Yanez received a grant of 50,000 shares of restricted common stock on May 4, 2026 as compensation under the company’s 2025 Equity Incentive Plan, subject to shareholder approval, increasing her direct holdings to 1,221,271 common shares.
SEARS SAMUEL P JR reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Samuel P. Sears Jr. received a grant of 50,000 shares of restricted common stock on May 4, 2026 as compensation under the 2025 Equity Incentive Plan, subject to shareholder approval. After this award, he directly holds 1,229,543 common shares.
ODONNELL FRANCIS E JR reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. reported that Chief Executive Officer Francis E. O'Donnell Jr. received a grant of 50,000 shares of restricted common stock on May 4, 2026, at $0.00 per share as compensation under the 2025 Equity Incentive Plan, subject to shareholder approval. Following this award, he directly holds a total of 150,000 common shares.
Jerman Michael Allen reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Jerman Michael Allen received a grant of 50,000 shares of restricted common stock as compensation under the company’s 2025 Equity Incentive Plan. Following this award, he directly holds 180,411 shares of common stock, reflecting a routine equity-based compensation grant rather than an open-market trade.
Vasisht Niraj reported acquisition or exercise transactions in this Form 4 filing.
Inhibitor Therapeutics, Inc. director Niraj Vasisht received a grant of 50,000 shares of restricted common stock as compensation under the company’s 2025 Equity Incentive Plan. The grant was recorded at a price of $0.00 per share, and his directly held common stock position increased to 200,000 shares following this award.